BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:COMPASS Pathways readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies COMPASS Pathways's drugs run\, fr
 om ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07570654-855@assetmemo.bio
DTSTAMP:20261121T004440Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Psilocybin (COMP360): Phase 2/3 readout est. (NCT07570654)
DESCRIPTION:Psilocybin (COMP360)\, phase 2/3\, Post-Traumatic Stress Disord
 er.\nStudy: Redefine Study: A Study Evaluating the Efficacy\, Safety\, and
  Tolerability of COMP360 in Participants With Post-traumatic Stress Disord
 er\nEstimated primary completion: November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/psilocybin-comp360#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07570654
URL:https://assetmemo.bio/drug/psilocybin-comp360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
